Brawn Biotech Ltd vs DIVI S LABORATORIES LTD

A side-by-side comparison of Brawn Biotech Ltd (BRAWNPHARMACEUTICALSLTD) and DIVI S LABORATORIES LTD (DIVISLAB) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads BRAWNPHARMACEUTICALSLTD vs DIVISLAB on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability13
  • Growth01
  • Size & financial health03
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

8.00
P/E ratio
95.04
1.59
P/B ratio
10.62
0.00%
Dividend yield
0.33%
₹-5.80
EPS
₹96.73

Profitability

DIVISLAB takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

24.40%
Return on equity
16.50%
-42.52%
Return on capital
22.00%
-13.15%
EBITDA margin
33.00%
-12.93%
Net margin
24.32%

Growth

DIVISLAB takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-8.59%
Revenue CAGR (3Y)
10.78%
Profit CAGR (3Y) even
12.10%

Size & financial health

DIVISLAB takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹7 Cr
Market cap
₹2.43L Cr
₹13 Cr
Revenue
₹10,560 Cr
₹-2 Cr
Net profit
₹2,568 Cr
0.00
Debt / equity even
0.00
Brawn Biotech Ltd
  • + ["Company is almost debt free.", "Company's working capital requirements have reduced from 130 days to 35.9 days"]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of -13.5% over past five years.", "Company has a low return on equity of -14.8% over last 3 years."]
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Brawn Biotech Ltd full analysis DIVI S LABORATORIES LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

BRAWNPHARMACEUTICALSLTD vs DIVISLAB: Share Price, Valuation & Which to Buy | DocStoX